The significant reversal of resistance in BC cells to trastuzumab and lapatinib has been achieved through genetic knockout and pharmacological inhibition of GLUT4, as well as interfering with ALKBH5 to suppress GLUT4 expression. Here, SLC2A4 is linked to breast cancer.